BAM
ABMD

Belpointe Asset Management’s Abiomed Inc ABMD Stock Holding History

Belpointe Asset Management’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-451
Closed -$125K – 993
2020
Q3 		$125K Buy
+451
New +$130K 0.01% 697

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Belpointe Asset Management's ABMD Position: Q4 2020 in Review

Belpointe Asset Management sold out of Abiomed Inc (ABMD) in Q4 2020, closing a stake of 451 shares — an estimated $125K sold.

Belpointe Asset Management first reported a position in ABMD in Q3 2020 and held it in 1 quarter. The position peaked at $125K in Q3 2020. 498 funds tracked by Wall St. Rank hold ABMD as of Q4 2020.

  • Belpointe Asset Management reported no remaining Abiomed Inc position as of Q4 2020 after selling out during the quarter.
  • Belpointe Asset Management sold 451 Abiomed Inc shares in Q4 2020, an estimated $125K.
  • Belpointe Asset Management first reported a position in Abiomed Inc in Q3 2020 and held it in 1 quarter.
  • Belpointe Asset Management's Abiomed Inc position peaked at $125K in Q3 2020.
  • 498 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2020.

Based on Belpointe Asset Management's 13F filing for Q4 2020, filed 16 Feb 2021.